Design and conduct considerations for studies in patients with hepatic impairment
Open Access
- 9 October 2022
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (1) , 50-61
Abstract
Despite the liver being the primary site for clearance of xenobiotics utilizing a myriad of mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary excretion, there is a dearth of information available as to how the severity of hepatic impairment (HI) can alter drug absorption and disposition (i.e., pharmacokinetics [PK]) as well as their efficacy and safety or pharmacodynamics (PD). In general, regulatory agencies recommend conducting PK studies in subjects with HI when hepatic metabolism/excretion accounts for more than 20% of drug elimination or if the drug has a narrow therapeutic range. In this tutorial, we provide an overview of the global regulatory landscape, clinical measures for hepatic function assessment, methods to stage HI severity, and consequently the impact on labeling. In addition, we provide an in‐depth practical guidance for designing and conducting clinical trials for patients with HI and on the application of modeling and simulation strategies in lieu of dedicated trials for dosing recommendations in patients with HI.Keywords
This publication has 47 references indexed in Scilit:
- Hepatic Clearance of Drugs in Patients With Renal InsufficiencyClinical Pharmacology in Drug Development, 2013
- A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug ClearanceClinical Pharmacokinetics, 2010
- Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557Antimicrobial Agents and Chemotherapy, 2009
- Reduced Duodenal Cytochrome P450 3A Protein Expression and Catalytic Activity in Patients With CirrhosisClinical Pharmacology & Therapeutics, 2009
- Simulation and prediction of in vivo drug metabolism in human populations from in vitro dataNature Reviews Drug Discovery, 2007
- Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006
- Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous CortisolJournal of Clinical Oncology, 2005
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomitingCancer, 2003
- Lidocaine Metabolite Formation as a Measure of Liver Function in Patients with CirrhosisTherapeutic Drug Monitoring, 1990
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973